|Articles|April 1, 2011

Pharmaceutical Executive

  • Pharmaceutical Executive-04-01-2011
  • Volume 0
  • Issue 0

iLogistica

Ilogistica has built a brand new warehouse facility with the latest technology to keep up with outsourcing demands

With the reform of CENABAST requiring the outsourcing of all its distribution activities, logistics providers are stepping up to meet the demand of pharmaceutical laboratories. Just outside of Santiago, iLogistica has built a brand new 8,000m2 storage warehouse with the latest technology for the most efficient distribution of pharmaceutical products. Having reconstructed almost from scratch after the earthquake in February of 2010, the company has refurbished itself to become the strategic partner for the industry. General manager, Raul Zamorano, explains his company's comparative advantage to serve the pharmaceutical industry: "being an entirely independent company that is not linked to any pharmaceutical laboratory, we can ensure the utmost confidentiality of our clients' data and product information. We also have no alliance with any of the players in the industry and this allows us to act freely always looking to serve our clients in the most efficient and effective way possible. In this sense we are positioned to become a trustworthy partner for any international company that wishes to distribute their products in Chile and who might have reservations about the safety of their company's data." The company has gone as far as developing a custom-made software platform that allows the greatest adaptability to the demands of its customers. "In order to provide the best traceability for our clients we have developed our own software platform that allows full customization to each one of our clients' needs," explains Zamorano.

Raul Zamorano, General Manager, iLogistica

iLogistica Santiago warehouse

Articles in this issue

over 15 years ago

Off-Label But On Point?

over 15 years ago

Pharm Exec Wins a Neal Award!

over 15 years ago

Espacio Riesco

over 15 years ago

Restoring Public Trust in Pharma

over 15 years ago

Revisiting Reform

Related to this article

Pharmaceutical Executive Daily
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Naoki Okamura: Post-Patent Plan and Purpose
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.